Global Biosimilars Treatment Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Biosimilars Treatment Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal Biosimilars Treatment Market
Global Biosimilars Treatment market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Biosimilars Treatment industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Biosimilars Treatment market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Biosimilars Treatment market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report

By Company

Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Segment by Type
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides

Segment by Application

Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline

Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Biosimilars Treatment introduction, etc. Biosimilars Treatment Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Biosimilars Treatment
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Recombinant Non – Glycosylated Proteins
1.2.3 Recombinant Glycosylated Proteins
1.2.4 Recombinant Peptides
1.3 Market by Application
1.3.1 Global Biosimilars Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Oncology
1.3.3 Chronic and Autoimmune Disease
1.3.4 Blood Disorders
1.3.5 Growth Hormone Disease
1.3.6 Infectious Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars Treatment Market Perspective (2018-2033)
2.2 Global Biosimilars Treatment Growth Trends by Region
2.2.1 Biosimilars Treatment Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Biosimilars Treatment Historic Market Size by Region (2018-2023)
2.2.3 Biosimilars Treatment Forecasted Market Size by Region (2024-2033)
2.3 Biosimilars Treatment Market Dynamics
2.3.1 Biosimilars Treatment Industry Trends
2.3.2 Biosimilars Treatment Market Drivers
2.3.3 Biosimilars Treatment Market Challenges
2.3.4 Biosimilars Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Biosimilars Treatment by Players
3.1.1 Global Biosimilars Treatment Revenue by Players (2018-2023)
3.1.2 Global Biosimilars Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Biosimilars Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Biosimilars Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Biosimilars Treatment Market Concentration Ratio
3.4.1 Global Biosimilars Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars Treatment Revenue in 2022
3.5 Global Key Players of Biosimilars Treatment Head office and Area Served
3.6 Global Key Players of Biosimilars Treatment, Product and Application
3.7 Global Key Players of Biosimilars Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilars Treatment Breakdown Data by Type
4.1 Global Biosimilars Treatment Historic Market Size by Type (2018-2023)
4.2 Global Biosimilars Treatment Forecasted Market Size by Type (2024-2033)
5 Biosimilars Treatment Breakdown Data by Application
5.1 Global Biosimilars Treatment Historic Market Size by Application (2018-2023)
5.2 Global Biosimilars Treatment Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Biosimilars Treatment Market Size (2018-2033)
6.2 North America Biosimilars Treatment Market Size by Type
6.2.1 North America Biosimilars Treatment Market Size by Type (2018-2023)
6.2.2 North America Biosimilars Treatment Market Size by Type (2024-2033)
6.2.3 North America Biosimilars Treatment Market Share by Type (2018-2033)
6.3 North America Biosimilars Treatment Market Size by Application
6.3.1 North America Biosimilars Treatment Market Size by Application (2018-2023)
6.3.2 North America Biosimilars Treatment Market Size by Application (2024-2033)
6.3.3 North America Biosimilars Treatment Market Share by Application (2018-2033)
6.4 North America Biosimilars Treatment Market Size by Country
6.4.1 North America Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Biosimilars Treatment Market Size by Country (2018-2023)
6.4.3 North America Biosimilars Treatment Market Size by Country (2024-2033)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Biosimilars Treatment Market Size (2018-2033)
7.2 Europe Biosimilars Treatment Market Size by Type
7.2.1 Europe Biosimilars Treatment Market Size by Type (2018-2023)
7.2.2 Europe Biosimilars Treatment Market Size by Type (2024-2033)
7.2.3 Europe Biosimilars Treatment Market Share by Type (2018-2033)
7.3 Europe Biosimilars Treatment Market Size by Application
7.3.1 Europe Biosimilars Treatment Market Size by Application (2018-2023)
7.3.2 Europe Biosimilars Treatment Market Size by Application (2024-2033)
7.3.3 Europe Biosimilars Treatment Market Share by Application (2018-2033)
7.4 Europe Biosimilars Treatment Market Size by Country
7.4.1 Europe Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Biosimilars Treatment Market Size by Country (2018-2023)
7.4.3 Europe Biosimilars Treatment Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Biosimilars Treatment Market Size (2018-2033)
8.2 China Biosimilars Treatment Market Size by Type
8.2.1 China Biosimilars Treatment Market Size by Type (2018-2023)
8.2.2 China Biosimilars Treatment Market Size by Type (2024-2033)
8.2.3 China Biosimilars Treatment Market Share by Type (2018-2033)
8.3 China Biosimilars Treatment Market Size by Application
8.3.1 China Biosimilars Treatment Market Size by Application (2018-2023)
8.3.2 China Biosimilars Treatment Market Size by Application (2024-2033)
8.3.3 China Biosimilars Treatment Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Biosimilars Treatment Market Size (2018-2033)
9.2 Asia Biosimilars Treatment Market Size by Type
9.2.1 Asia Biosimilars Treatment Market Size by Type (2018-2023)
9.2.2 Asia Biosimilars Treatment Market Size by Type (2024-2033)
9.2.3 Asia Biosimilars Treatment Market Share by Type (2018-2033)
9.3 Asia Biosimilars Treatment Market Size by Application
9.3.1 Asia Biosimilars Treatment Market Size by Application (2018-2023)
9.3.2 Asia Biosimilars Treatment Market Size by Application (2024-2033)
9.3.3 Asia Biosimilars Treatment Market Share by Application (2018-2033)
9.4 Asia Biosimilars Treatment Market Size by Region
9.4.1 Asia Biosimilars Treatment Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Biosimilars Treatment Market Size by Region (2018-2023)
9.4.3 Asia Biosimilars Treatment Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Biosimilars Treatment Introduction
11.1.4 Bayer Revenue in Biosimilars Treatment Business (2018-2023)
11.1.5 Bayer Recent Developments
11.2 Eli Lily, Inc.
11.2.1 Eli Lily, Inc. Company Details
11.2.2 Eli Lily, Inc. Business Overview
11.2.3 Eli Lily, Inc. Biosimilars Treatment Introduction
11.2.4 Eli Lily, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.2.5 Eli Lily, Inc. Recent Developments
11.3 Pfizer, Inc.
11.3.1 Pfizer, Inc. Company Details
11.3.2 Pfizer, Inc. Business Overview
11.3.3 Pfizer, Inc. Biosimilars Treatment Introduction
11.3.4 Pfizer, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.3.5 Pfizer, Inc. Recent Developments
11.4 Sandoz International GmbH
11.4.1 Sandoz International GmbH Company Details
11.4.2 Sandoz International GmbH Business Overview
11.4.3 Sandoz International GmbH Biosimilars Treatment Introduction
11.4.4 Sandoz International GmbH Revenue in Biosimilars Treatment Business (2018-2023)
11.4.5 Sandoz International GmbH Recent Developments
11.5 Teva Pharmaceutical Industries Limited
11.5.1 Teva Pharmaceutical Industries Limited Company Details
11.5.2 Teva Pharmaceutical Industries Limited Business Overview
11.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Limited Revenue in Biosimilars Treatment Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Limited Recent Developments
11.6 Amgen Inc.
11.6.1 Amgen Inc. Company Details
11.6.2 Amgen Inc. Business Overview
11.6.3 Amgen Inc. Biosimilars Treatment Introduction
11.6.4 Amgen Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.6.5 Amgen Inc. Recent Developments
11.7 Biocon
11.7.1 Biocon Company Details
11.7.2 Biocon Business Overview
11.7.3 Biocon Biosimilars Treatment Introduction
11.7.4 Biocon Revenue in Biosimilars Treatment Business (2018-2023)
11.7.5 Biocon Recent Developments
11.8 Dr. Reddy’s Laboratories
11.8.1 Dr. Reddy’s Laboratories Company Details
11.8.2 Dr. Reddy’s Laboratories Business Overview
11.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Introduction
11.8.4 Dr. Reddy’s Laboratories Revenue in Biosimilars Treatment Business (2018-2023)
11.8.5 Dr. Reddy’s Laboratories Recent Developments
11.9 Roche Ltd.
11.9.1 Roche Ltd. Company Details
11.9.2 Roche Ltd. Business Overview
11.9.3 Roche Ltd. Biosimilars Treatment Introduction
11.9.4 Roche Ltd. Revenue in Biosimilars Treatment Business (2018-2023)
11.9.5 Roche Ltd. Recent Developments
11.10 Celltrion, Inc.
11.10.1 Celltrion, Inc. Company Details
11.10.2 Celltrion, Inc. Business Overview
11.10.3 Celltrion, Inc. Biosimilars Treatment Introduction
11.10.4 Celltrion, Inc. Revenue in Biosimilars Treatment Business (2018-2023)
11.10.5 Celltrion, Inc. Recent Developments
11.11 Samsung Bioepis
11.11.1 Samsung Bioepis Company Details
11.11.2 Samsung Bioepis Business Overview
11.11.3 Samsung Bioepis Biosimilars Treatment Introduction
11.11.4 Samsung Bioepis Revenue in Biosimilars Treatment Business (2018-2023)
11.11.5 Samsung Bioepis Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Biosimilars Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Recombinant Non – Glycosylated Proteins
Table 3. Key Players of Recombinant Glycosylated Proteins
Table 4. Key Players of Recombinant Peptides
Table 5. Global Biosimilars Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 6. Global Biosimilars Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Biosimilars Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Biosimilars Treatment Market Share by Region (2018-2023)
Table 9. Global Biosimilars Treatment Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Biosimilars Treatment Market Share by Region (2024-2033)
Table 11. Biosimilars Treatment Market Trends
Table 12. Biosimilars Treatment Market Drivers
Table 13. Biosimilars Treatment Market Challenges
Table 14. Biosimilars Treatment Market Restraints
Table 15. Global Biosimilars Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Biosimilars Treatment Revenue Share by Players (2018-2023)
Table 17. Global Top Biosimilars Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2022)
Table 18. Global Biosimilars Treatment Industry Ranking 2021 VS 2022 VS 2023
Table 19. Global 5 Largest Players Market Share by Biosimilars Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 20. Global Key Players of Biosimilars Treatment, Headquarters and Area Served
Table 21. Global Key Players of Biosimilars Treatment, Product and Application
Table 22. Global Key Players of Biosimilars Treatment, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Biosimilars Treatment Revenue Market Share by Type (2018-2023)
Table 26. Global Biosimilars Treatment Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Biosimilars Treatment Revenue Market Share by Type (2024-2033)
Table 28. Global Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Biosimilars Treatment Revenue Share by Application (2018-2023)
Table 30. Global Biosimilars Treatment Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Biosimilars Treatment Revenue Share by Application (2024-2033)
Table 32. North America Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 33. North America Biosimilars Treatment Market Size by Type (2024-2033) & (US$ Million)
Table 34. North America Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 35. North America Biosimilars Treatment Market Size by Application (2024-2033) & (US$ Million)
Table 36. North America Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. North America Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Biosimilars Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 39. Europe Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 40. Europe Biosimilars Treatment Market Size by Type (2024-2033) & (US$ Million)
Table 41. Europe Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 42. Europe Biosimilars Treatment Market Size by Application (2024-2033) & (US$ Million)
Table 43. Europe Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Europe Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Europe Biosimilars Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 46. China Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 47. China Biosimilars Treatment Market Size by Type (2024-2033) & (US$ Million)
Table 48. China Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 49. China Biosimilars Treatment Market Size by Application (2024-2033) & (US$ Million)
Table 50. Asia Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 51. Asia Biosimilars Treatment Market Size by Type (2024-2033) & (US$ Million)
Table 52. Asia Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 53. Asia Biosimilars Treatment Market Size by Application (2024-2033) & (US$ Million)
Table 54. Asia Biosimilars Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 55. Asia Biosimilars Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 56. Asia Biosimilars Treatment Market Size by Region (2024-2033) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Type (2024-2033) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Application (2024-2033) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Biosimilars Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 62. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Biosimilars Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 64. Bayer Company Details
Table 65. Bayer Business Overview
Table 66. Bayer Biosimilars Treatment Product
Table 67. Bayer Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 68. Bayer Recent Developments
Table 69. Eli Lily, Inc. Company Details
Table 70. Eli Lily, Inc. Business Overview
Table 71. Eli Lily, Inc. Biosimilars Treatment Product
Table 72. Eli Lily, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 73. Eli Lily, Inc. Recent Developments
Table 74. Pfizer, Inc. Company Details
Table 75. Pfizer, Inc. Business Overview
Table 76. Pfizer, Inc. Biosimilars Treatment Product
Table 77. Pfizer, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 78. Pfizer, Inc. Recent Developments
Table 79. Sandoz International GmbH Company Details
Table 80. Sandoz International GmbH Business Overview
Table 81. Sandoz International GmbH Biosimilars Treatment Product
Table 82. Sandoz International GmbH Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 83. Sandoz International GmbH Recent Developments
Table 84. Teva Pharmaceutical Industries Limited Company Details
Table 85. Teva Pharmaceutical Industries Limited Business Overview
Table 86. Teva Pharmaceutical Industries Limited Biosimilars Treatment Product
Table 87. Teva Pharmaceutical Industries Limited Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 88. Teva Pharmaceutical Industries Limited Recent Developments
Table 89. Amgen Inc. Company Details
Table 90. Amgen Inc. Business Overview
Table 91. Amgen Inc. Biosimilars Treatment Product
Table 92. Amgen Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 93. Amgen Inc. Recent Developments
Table 94. Biocon Company Details
Table 95. Biocon Business Overview
Table 96. Biocon Biosimilars Treatment Product
Table 97. Biocon Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 98. Biocon Recent Developments
Table 99. Dr. Reddy’s Laboratories Company Details
Table 100. Dr. Reddy’s Laboratories Business Overview
Table 101. Dr. Reddy’s Laboratories Biosimilars Treatment Product
Table 102. Dr. Reddy’s Laboratories Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 103. Dr. Reddy’s Laboratories Recent Developments
Table 104. Roche Ltd. Company Details
Table 105. Roche Ltd. Business Overview
Table 106. Roche Ltd. Biosimilars Treatment Product
Table 107. Roche Ltd. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 108. Roche Ltd. Recent Developments
Table 109. Celltrion, Inc. Company Details
Table 110. Celltrion, Inc. Business Overview
Table 111. Celltrion, Inc. Biosimilars Treatment Product
Table 112. Celltrion, Inc. Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 113. Celltrion, Inc. Recent Developments
Table 114. Samsung Bioepis Company Details
Table 115. Samsung Bioepis Business Overview
Table 116. Samsung Bioepis Biosimilars Treatment Product
Table 117. Samsung Bioepis Revenue in Biosimilars Treatment Business (2018-2023) & (US$ Million)
Table 118. Samsung Bioepis Recent Developments
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Biosimilars Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Biosimilars Treatment Market Share by Type: 2022 VS 2033
Figure 3. Recombinant Non – Glycosylated Proteins Features
Figure 4. Recombinant Glycosylated Proteins Features
Figure 5. Recombinant Peptides Features
Figure 6. Global Biosimilars Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 7. Global Biosimilars Treatment Market Share by Application: 2022 VS 2033
Figure 8. Oncology Case Studies
Figure 9. Chronic and Autoimmune Disease Case Studies
Figure 10. Blood Disorders Case Studies
Figure 11. Growth Hormone Disease Case Studies
Figure 12. Infectious Disease Case Studies
Figure 13. Biosimilars Treatment Report Years Considered
Figure 14. Global Biosimilars Treatment Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Biosimilars Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Biosimilars Treatment Market Share by Region: 2022 VS 2033
Figure 17. Global Biosimilars Treatment Market Share by Players in 2022
Figure 18. Global Top Biosimilars Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Biosimilars Treatment Revenue in 2022
Figure 20. North America Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Biosimilars Treatment Market Share by Type (2018-2033)
Figure 22. North America Biosimilars Treatment Market Share by Application (2018-2033)
Figure 23. North America Biosimilars Treatment Market Share by Country (2018-2033)
Figure 24. United States Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Canada Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe Biosimilars Treatment Market Size YoY (2018-2033) & (US$ Million)
Figure 27. Europe Biosimilars Treatment Market Share by Type (2018-2033)
Figure 28. Europe Biosimilars Treatment Market Share by Application (2018-2033)
Figure 29. Europe Biosimilars Treatment Market Share by Country (2018-2033)
Figure 30. Germany Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. France Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. U.K. Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Italy Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Russia Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Nordic Countries Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. China Biosimilars Treatment Market Size YoY (2018-2033) & (US$ Million)
Figure 37. China Biosimilars Treatment Market Share by Type (2018-2033)
Figure 38. China Biosimilars Treatment Market Share by Application (2018-2033)
Figure 39. Asia Biosimilars Treatment Market Size YoY (2018-2033) & (US$ Million)
Figure 40. Asia Biosimilars Treatment Market Share by Type (2018-2033)
Figure 41. Asia Biosimilars Treatment Market Share by Application (2018-2033)
Figure 42. Asia Biosimilars Treatment Market Share by Region (2018-2033)
Figure 43. Japan Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. South Korea Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. China Taiwan Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Southeast Asia Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. India Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Australia Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Biosimilars Treatment Market Size YoY (2018-2033) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Type (2018-2033)
Figure 51. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Application (2018-2033)
Figure 52. Middle East, Africa, and Latin America Biosimilars Treatment Market Share by Country (2018-2033)
Figure 53. Brazil Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Mexico Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Turkey Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Saudi Arabia Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Israel Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. GCC Countries Biosimilars Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 59. Bayer Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 60. Eli Lily, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 61. Pfizer, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 62. Sandoz International GmbH Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 63. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 64. Amgen Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 65. Biocon Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 66. Dr. Reddy’s Laboratories Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 67. Roche Ltd. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 68. Celltrion, Inc. Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 69. Samsung Bioepis Revenue Growth Rate in Biosimilars Treatment Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Global Biosimilars Treatment Market Insights, Forecast to 2034

Global Biosimilars Treatment Market Insights, Forecast to 2034

By Company

Segment by Application

Chapter Outline

Table of Content

List of Figure

Select User License

$4200 Single Licence

$6000 Enterprise Licence

$9100 Corporate Licence

Note : All prices in USD

FAQ'S

User License?

Delivery Time?

How do I place an order?

What is the Payment Options?

Is there a discount for multiple purchases?

Mode of Report Delivery?

Top Industries